Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Organisation › Details

Resalis Therapeutics S.r.l.

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders. *

 

Period Start 2021-01-01 established
Products Industry RES-010 (Resalis Therapeutics, antisense oligonucleotide targeting miR-22)
  Industry 2 non-coding RNA
Persons Person Toniolo, Alessandro (Resalis Therapeutics 202302 CEO before Pfizer + Novartis)
  Person 2 Puglisi, Pietro (Claris Ventures 201907 Managing Partner + Co-Founder)
     
Region Region Torino (Turin) (TO)
  Country Italy
  Street 52 Via Nizza
  City 10126 Torino (TO)
    Address record changed: 2023-03-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: Resalis Therapeutics S.r.l.. (2/22/23). "Press Release: Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases". Torino.
     
   
Record changed: 2024-01-07

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Resalis Therapeutics S.r.l.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x300px




» top